Potassium Ion

Potassium Ion

SCHEMBL224967

CC1=Nc2ccc(S(=O)(=O)[O-])cc2C1(C)C.[K+]

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA

The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Potassium Ion SCHEMBL29727670 1.00 LMNA (0.41) LMNATDP1MEN1KMT2A
SCHEMBL2721232 0.97 LMNA (0.44) LMNATDP1MEN1KMT2A
SCHEMBL47326 0.85 RXRA (0.37) LMNATDP1MEN1KMT2A
SCHEMBL29869219 0.85 RXRA (0.37) LMNATDP1MEN1KMT2A
SCHEMBL11852597 0.85 G6PD (0.38) LMNAMEN1KMT2A
SCHEMBL13962645 0.84 ALDH1A1 (0.34) TDP1MEN1KMT2A
SCHEMBL224968 0.84 RXRA (0.36) LMNATDP1MEN1KMT2A
SCHEMBL6027095 0.84 MAPT (0.42) LMNAMEN1KMT2A
Potassium SCHEMBL559580 0.84 RXRA (0.36) LMNATDP1MEN1KMT2A
SCHEMBL2721236 0.84 RXRA (0.36) LMNATDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113337138-B Indole cyanine dye 天津全和诚科技有限责任公司 2022-08-09 CN claimed
CN-113462186-A sulfo-Cy 3 carboxylic acid fluorescent dye and preparation process thereof 江西高信前沿科技有限公司 2021-10-01 CN claimed
CN-113337138-A Novel indole cyanine dye 天津全和诚科技有限责任公司 2021-09-03 CN claimed
US-20260117070-A1 NEAR-INFRARED FLUORESCENT HEPTAMETHINE DYE CONJUGATES WITH FAVORABLE BLEACHING PROPERTIES HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) 2026-04-30 US disclosed
US-20250275943-A1 COMPOSITION FOR CANCER DIAGNOSIS TARGETING TUMOR AND/OR TUMOR MICROENVIRONMENT AND USE THEREOF The General Hospital Cooperation d/b/a Massachusetts General Hospital (MGH) 2025-09-04 US disclosed
WO-2025095666-A1 NOVEL OXOCYANINE-BASED COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF 포항공과대학교 산학협력단 2025-05-08 WO disclosed
EP-4529551-A1 NEAR-INFRARED FLUORESCENT HEPTAMETHINE DYE CONJUGATES WITH FAVORABLE BLEACHING PROPERTIES Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) 2025-04-02 EP disclosed
WO-2023227601-A1 NEAR-INFRARED FLUORESCENT HEPTAMETHINE DYE CONJUGATES WITH FAVORABLE BLEACHING PROPERTIES Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) 2023-11-30 WO disclosed
US-20220387632-A1 RENAL CLEARABLE FLUORESCENT CONTRAST AGENT WITH INCREASED TUMOR SPECIFICITY, AND IMAGING METHOD USING SAME NAWOOVISION CO., LTD. (KP) 2022-12-08 US disclosed
CN-113337138-B Indole cyanine dye 天津全和诚科技有限责任公司 2022-08-09 CN disclosed
US-20210338841-A1 Imaging Agents SCINTOMICS GMBH (DE) 2021-11-04 US disclosed
US-6538129-B1 Luminescent compounds Terpetschnig, Ewald A. 2003-03-25 US disclosed
US-6448008-B1 IMMUNOLOGICAL BINDING REAGENT LABELLED WITH A FLUORESCENT COMPOUND AND METHOD OF ASSAYING AN ANALYTE IN A SAMPLE COMPRISING CONTACTING A NUCLEIC ACID PROBE OR AN IMMUNOLOGICALLY BINDING REAGENT LABELLED WITH A FLUORESCENT INNOSENSE, S.R.L. (IT) 2002-09-10 US disclosed
EP-0898596-B1 SQUARATE DYES AND THEIR USE IN FLUORESCENT SEQUENCING METHOD AMERSHAM PHARM BIOTECH UK LTD (GB) 2001-08-29 EP disclosed
EP-1078023-A1 LUMINESCENT COMPOUNDS Terpetschnig, Ewald A. (US) 2001-02-28 EP disclosed
EP-1065250-A1 New fluorescent cyanine labels containing a sulfamido linker arm Innosense S.r.l. (IT) 2001-01-03 EP disclosed
US-6140494-A INCREASED WATER SOLUBILITY, INCREASED PHOTOSTABILITY, BRIGHTNESS AND THE POTENTIAL REDUCTION OF INTERACTIONS WITH SURROUNDINGS AMERSHAM PHARMACIA BIOTECH UK LIMITED (GB) 2000-10-31 US disclosed
WO-1999051702-A1 LUMINESCENT COMPOUNDS TERPETSCHNIG EWALD A (US) 1999-10-14 WO disclosed
EP-0898596-A1 SQUARATE DYES AND THEIR USE IN FLUORESCENT SEQUENCING METHOD Amersham Pharmacia Biotech UK Limited (GB) 1999-03-03 EP disclosed
WO-1997040104-A1 SQUARATE DYES AND THEIR USE IN FLUORESCENT SEQUENCING METHOD AMERSHAM PHARMACIA BIOTECH UK LIMITED (GB) 1997-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260117070-A1 NEAR-INFRARED FLUORESCENT HEPTAMETHINE DYE CONJUGATES WITH FAVORABLE BLEACHING PROPERTIES CBR1, CBR3, NR2E3 LMNA 1557/4885TDP1 3164/4885MEN1 2322/4885
US-20210338841-A1 Imaging Agents HNRNPF, ANXA5, TFEB LMNA 1392/4885TDP1 1059/4885MEN1 775/4885
US-20220387632-A1 RENAL CLEARABLE FLUORESCENT CONTRAST AGENT WITH INCREASED TUMOR SPECIFICITY, AND IMAGING METHOD USING SAME RCC2, REN, VHL LMNA 3256/4885TDP1 4513/4885MEN1 129/4885
US-20250275943-A1 COMPOSITION FOR CANCER DIAGNOSIS TARGETING TUMOR AND/OR TUMOR MICROENVIRONMENT AND USE THEREOF FOLR1, FOLR2, MSR1 LMNA 3002/4885TDP1 4237/4885MEN1 996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.